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Introduction 
A new environment for vaccines is emerging. 
Vaccines are one of the most cost-effective public 
health interventions and are critical to meeting the 
United Nations Millennium Development Goal of 
reducing deaths among children less than five years 
old.  In the past decade, the rate at which new 
vaccines have been introduced into the world market 
has been unprecedented (see Figure 1).  The 
pipeline of vaccine development addresses some of 
the biggest causes of child mortality, including 
malaria (WHO, UNICEF, World Bank, 2009).     
Furthermore, funding for the adoption of such 
vaccines by low-income countries is made available 
by the GAVI Alliance, a public-private partnership 
that co-finances the purchase of a set of pre-
qualified vaccines by countries deemed eligible 
based on socio-economic status. 
However, given the finite capacity of vaccine 
delivery systems, finite sources of funding and 
varying disease burden, countries will be faced with 
the need to choose which vaccines to adopt into 
their national immunization programs in the coming 
years. Therefore, just as proliferation of stock-
keeping units or product variety is increasing implied 
demand uncertainty in commercial supply chains 
(Chopra and Meindl, 2010), the rapid introduction of 
new vaccines creates a more uncertain adoption 
landscape, making it more difficult for supply to meet 
demand.   
Forecasting these adoption dates is an important 
pre-requisite to forecasting global demand for 
vaccine doses, which in turn is essential for different 
stakeholders in the global vaccine supply chain – for 
planning production capacity, for projecting funding 
requirements, and for designing or expanding the 
appropriate supply chain infrastructure (Sekhri, 
2008). 
GAVI has teamed up with the Program for 
Appropriate Technologies in Health (PATH) to 
develop a platform for the strategic forecasting of 
vaccine demand.  This independent study was 
conducted with a view to recommending how long-
term adoption dates might be fed into the overall 
demand forecasting process, so as to inform and 
facilitate strategic planning by GAVI and other 
stakeholders in the global supply chain for vaccines. 
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KEY INSIGHTS 
1. Forecasts can no longer look at vaccines
individually but must consider the portfolio of
vaccines that countries adopt.
2. A rule-based approach that uses adoption
preferences, spacing and “look-ahead”
captures the dynamics of such
concomitancy.
3. Pending adoptions will continue to
accumulate and should be measured in the
long-run to inform objectives and policies.
 Figure 1 
 
A Rule-Based Forecasting Model 
 
This thesis uses findings from literature, data 
analysis and expert opinion to propose a rule-based 
model to forecast vaccine adoption dates for GAVI-
eligible countries over 20 years.   
 
The resulting model incorporates three elements 
that shape a country’s adoption schedule: 
preferences (a country’s prioritization of some 
vaccines over others), spacing (the number of years 
between vaccine adoptions), and look-ahead 
(countries’ delay of current adoption in anticipation 
of important vaccines in the development pipeline). 
 
Preference tables are developed for the WHO sub-
regions based on regional disease burden.  These 
tables are then modified to account for GAVI co-
financing.  The change that GAVI co-financing 
brings to a country’s preference is a function of 
vaccine coverage rates and national income. 
 
The spacing of adoption is forecast to be two, three 
or five years, based on recent estimates of national 
coverage rates for the third dose of the diphtheria-
tetanus-pertussis vaccine (DTP3), which has served 
as a representation of the strength of a country’s 
vaccine delivery system.   
 
The model also includes pipeline anticipation, where 
countries are able to “look-ahead” to the introduction 
of important vaccines into the market, thereby 
allowing the model to predict how some countries 
can wait for these vaccines rather than adopt those 
that, while already available, are also less-preferred. 
 
 
Figure 2 
 
Results: Measuring the Effect of Concomitancy 
 
Sample forecasts using these rules show that 
adoption delays will continue to accumulate as a 
result of concomitancy.  These translate into missed 
opportunities at improving global health, which can 
be quantified using two proposed indicators:  
 
Weighted Country-Vaccine-Year Delays (CVYs) 
The number of years between a vaccine introduction 
and its adoption by a country, multiplied by the 
regional disease burden score for that vaccine in the 
country 
 
Weighted People-Vaccine-Year Delays (PVYs) 
CVY delays multiplied by the country’s population 
under 5 years old 
 
On a global scale, the missed opportunity is 20,963 
total CVYs or 125 trillion total PVYs by the year 
2030.  Figure 3 and Figure 4 show how these delays 
progress over time.  In these area stack charts, 
delays accumulate when years go by without 
vaccines being adopted.  On the other hand, the 
slope is reduced when countries begin to adopt the 
vaccines.  The areas are color-coded by coverage 
and income group. 
 
The accumulation of delays can be explained by two 
factors. The first is the spacing of adoption in 
relation to the introduction of new vaccines.  The 
least poor groups generally accumulate fewer 
delays.  The low coverage groups, on the other 
hand, drive the overall slope upward, since low 
coverage in the model translates to wider adoption 
spacing.   
 
The second factor is the look-ahead effect for the 
introduction of the malaria vaccine, especially for the 
African sub-regions.  As countries anticipate the 
malaria introduction, the adoption of other vaccines 
such as measles, pneumococcal, rotavirus, HPV, 
typhoid and shigellosis get put off. 
 
Additionally, CVY delays begin to drop towards the 
end of the forecast period, as there are no more 
additional pipeline vaccines being considered and 
countries have a chance to catch up on any relevant 
vaccines it had not adopted.  The drop in delays 
occurs sooner for the least poor countries than for 
low coverage countries and the rest. 
Conclusions 
This study sheds light on several key insights.  First, 
in a concomitant environment, forecasts can no 
longer look at vaccines individually but must 
consider vaccines concurrently, evaluating the 
portfolio of vaccines that countries adopt. 
 
Second, delayed adoptions will continue to 
accumulate as a result of concomitancy, translating 
into missed opportunities at improving global health.  
Measuring such delays is important in setting 
objectives and in evaluating alternative policies.  
This thesis proposes metrics within the adoption 
forecasting framework to do just that. 
 
Third, countries looking ahead in favor of preferred 
pipeline vaccines will increase the delays in 
adoptions even more.  Because of this effect, the 
issue of pipeline anticipation should be investigated 
further. 
 
Fourth, some of the older vaccines like measles may 
be left out as countries prioritize adoption based on 
disease burden and availability of GAVI co-
financing.   
 
Finally, countries most at risk in the concomitant 
environment are the poorest of GAVI-eligible 
countries that are starting the decade with low 
coverage of basic vaccines like DTP3. 
 
 
Figure 3 
 
Figure 4 
 
Further research should take into consideration 
vaccine affordability, state fragility, adoption 
difficulties like countries’ cold chain capacity, which 
are likely to affect preferences and spacing.    The 
thesis complements field work being done by PATH 
in Kenya, Tanzania and Zambia to characterize the 
current adoption logic used within the ministries of 
health, findings of which are due at the end of 2010.  
These may provide additional ideas to explore in 
further developing the model presented here.   
 
This study contributes to research by taking a 
valuable first step towards a complete framework for 
strategic adoption forecasting, one that is relevant to 
the new concomitant environment for GAVI-eligible 
countries.  It is the authors’ hope that this lays the 
groundwork for generating insights that will 
ultimately guide conversation and action. 
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